TLR9 Agonist May Reverse Resistance to Immune Checkpoint Inhibition in Melanoma

Leggi l'articolo originale


Treatment with the TLR9 agonist CMP-001 appeared to potentially reverse resistance to immune checkpoint inhibition in patients with metastatic melanoma.

Lascia un commento